From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma
Anish Thomas, Arun Rajan, Ariel López-Chávez et al. · Annals of Oncology · 2012
Cited by 62 works. doi:10.1093/annonc/mds478 Open-access PDF
Authors
References
- Optimal two-stage designs for phase II clinical trials
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- Sequencing technologies — the next generation
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2
- Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 1
- Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
- Detection of Mutations in EGFR in Circulating Lung-Cancer Cells
- High-throughput oncogene mutation profiling in human cancer
- ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers